Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

699
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
699
Drug Therapy01:28

Drug Therapy

445
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
445
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

1.2K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.2K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
Dysrhythmias VII: Nursing Management of Dysrhythmias01:25

Dysrhythmias VII: Nursing Management of Dysrhythmias

508
Nursing management of dysrhythmias involves the following:AssessmentSubjective Assessment:The initial step involves gathering patient-reported symptoms such as dizziness, palpitations, and chest discomfort. It is crucial to collect a detailed history, including previous heart conditions, current medication use, and lifestyle factors like caffeine and alcohol consumption.Objective Assessment:This involves observing clinical signs such as jugular venous distention, cool and pale skin, and...
508

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biosignatures of cognitive basic symptoms mark a distinct neurodevelopmental pathway to schizophrenia.

Brain : a journal of neurology·2026
Same author

Gray Matter Volume Abnormalities and the Association with the Trajectory of Symptoms and Functioning in Individuals at Clinical High Risk of Psychosis.

Schizophrenia bulletin·2025
Same author

Multimodal biological profiles of symptom-based subgroups in recent-onset psychosis.

Research square·2025
Same author

Association between non-adherence to fish oil or placebo as a risk factor of transition to psychosis in ultra-high-risk individuals in the NEURAPRO study.

The Australian and New Zealand journal of psychiatry·2025
Same author

From Snapshots to Stable Outcomes: Resting-State Functional Magnetic Resonance Imaging-Based Prognosis of Functioning in Patients With Psychosis Risk or Recent-Onset Depression.

Biological psychiatry·2025
Same author

Exploring the predictive value of structural covariance networks for the diagnosis of schizophrenia.

Frontiers in psychiatry·2025

Related Experiment Video

Updated: Apr 28, 2026

Self-Administration of Drugs in Mouse Models of Feeding and Obesity
03:37

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

4.3K

Symptom control, functioning and satisfaction among Swiss patients treated with risperidone long-acting injectable.

Beat Nick1, Roland Vauth, Daniel Braendle

  • 1Psychiatric Services Canton Solothurn, Solothurn, Switzerland.

International Journal of Psychiatry in Clinical Practice
|June 19, 2014
PubMed
Summary

Risperidone long-acting injectable (RLAI) significantly improved schizophrenia symptoms, patient satisfaction, and functioning in Swiss patients. This antipsychotic offers an effective option for long-term psychotic disorder management.

Keywords:
Schizophreniafunctioninglong-acting risperidonepatient satisfactiontolerability

More Related Videos

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
12:19

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression

Published on: April 10, 2026

200

Related Experiment Videos

Last Updated: Apr 28, 2026

Self-Administration of Drugs in Mouse Models of Feeding and Obesity
03:37

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

4.3K
Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
12:19

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression

Published on: April 10, 2026

200

Area of Science:

  • Psychiatry and Neuroscience
  • Pharmacology
  • Clinical Medicine

Background:

  • Schizophrenia and other psychotic disorders require effective long-term management.
  • Antipsychotic medication adherence is crucial for treatment success.
  • Long-acting injectable formulations offer an alternative for patients with adherence challenges.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of risperidone long-acting injectable (RLAI) in Swiss patients.
  • To assess RLAI in patients switching directly from previous antipsychotic treatments.
  • To investigate improvements in symptoms, functioning, and patient satisfaction.

Main Methods:

  • Sixty patients with schizophrenia or psychotic disorders were enrolled.
  • Patients received 25 mg RLAI every 2 weeks, with dosage adjustments possible.
  • The treatment duration was 6 months, with symptom and functioning assessments.

Main Results:

  • Significant reductions in total PANSS scores (P<0.001) and subscale scores were observed.
  • Improvements in Clinical Global Impression (CGI), Global Assessment of Functioning (GAF), and patient satisfaction were significant (P<0.001).
  • Significant reductions in Extrapyramidal Symptom Rating Scale (ESRS) scores, including Parkinsonism, were noted.

Conclusions:

  • RLAI demonstrated significant efficacy in improving psychotic disorder symptoms and patient functioning.
  • RLAI led to substantial improvements in patient satisfaction with treatment.
  • RLAI is a valuable option for the long-term management of patients with psychotic disorders, showing good tolerability and reduced movement disorders.